Business

Press Release Oct 31 2020

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 31, 2020, titled "Press Release Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA�� (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis".

articleSun Pharmaceutical Industries LimitedOctober 31, 20205/company/sun-pharmaceutical-industries-limited/news/press-release-oct-31-2020
Press Release Oct 31 2020

About this update from Sun Pharmaceutical Industries Limited

[{"type":"text","content":" Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 31, 2020, titled \"Press Release Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA�� (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis\". View Attachment","length":447,"tagName":"div"}]

More updates from Sun Pharmaceutical Industries Limited